Background: Periodontal disease negatively affects oral health-related quality of life (OHRQoL). While there is sufficient evidence for the clinical efficacy of periodontal therapy, data on patient-based outcomes are limited. Objectives: To systematically review the available evidence on the impact of periodontal therapy on OHRQoL in adults. Material & Methods: MEDLINE, EMBASE, CENTRAL and LILACS were searched without language restrictions. Longitudinal observational and intervention...

Dr. Keith Swetz, Assistant Professor of Medicine in the Department of General Internal Medicine and the Palliative Medicine program at Mayo Clinic in Rochester, MN, discusses his article appearing in the June 2011 issue of Mayo Clinic Proceedings on left ventricular assist devices as destination therapy. Available at: http://tinyurl.com/6kok6ga

Dr. Samuel Asirvatham, Professor of Medicine at the Mayo School of Medicine and a consultant in cardiac electrophysiology at Mayo Clinic in Rochester, MN, discusses his article "Perspectives on Withdrawing Pacemaker and Implantable Cardioverter-defibrillator Therapies at the End of Life: Results of a Survey of Medical and Legal Professionals and Patients," available online ( http://tinyurl.com/23kr8o5 ) and appearing in the November 2010 issue of Mayo Clinic Proceedings.

Michael Rogawski (University of California, Davis) summarizes his research on the antiepileptic activity of neurosteroids (e.g. ganaxolone, allopregnanolone). They are allosteric modulators of GABAA receptors and are active in many models of epilepsy. They are expected, however, to be most effective in catamenial epilepsy, infantile spasms or adult partial seizures. National Institutes of Health (NIH) is currently sponsoring a clinical trial of progesterone (precursor of allopregnanolone)...